Fresenius Medical Care AG & Co. KGaA

Earnings Release • Jul 25, 2013

Corporate Profile

Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for dialysis, a blood-filtering therapy replacing vital kidney functions for patients suffering from chronic kidney failure. Through its network of more than 3,200 dialysis clinics in over 40 countries, Fresenius Medical Care provides dialysis treatments to around 264,000 patients. With more than 40 production sites around the globe, the company is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Strategy

Our long-term strategy aims at sustainably increasing shareholder value. We focus our business activities on our patients' health and hence on the quality of treatment with the objective of improving their quality of life and raising their life expectancy.

As our previous growth strategy GOAL 13 comes to a close in 2013, we intend to set new goals in the current financial year that will allow us to maintain our outstanding market position and to be successful in the dialysis market. Basically we will continue along our growth paths in the future:

• Organic growth through expansion of our clinic network, initiation of innovative dialysis products and comprehensive treatment concepts,
• acquisitions, with focus on particularly attractive regions,
• horizontal expansion and
• a boosted activity in home therapies

Key figures - summary second quarter 2013

Net revenue	\$ 3,613 million	+5%
Operating income (EBIT), adjusted	\$ 555 million	-2%
Net income1 , adjusted	\$ 272 million	+2%
Earnings per share, adjusted	\$ 0.89	+2%
Total assets2	\$ 22,328 million
Operating cash flow	\$ 525 million	+16%

Goals for 2013

Net revenue	> \$14.6 billion
Net income1	\$1.1 billion – \$1.15 billion
Leverage ratio (Debt/EBITDA)	≤ 3.0
Capital expenditures	~ \$700 million
Acquisitions	~ \$500 million

Revenue second quarter 2013 per region (US\$ 3,613 m)

Management Board Supervisory Board

• Dr. Olaf Schermeier
• Kent Wanzek

• ¹ attributable to shareholders of Fresenius Medical Care AG & Co. KGaA ² as of June 30, 2013

• Rice Powell (Chairman) Dr. Gerd Krick (Chairman)

• Michael Brosnan Dr. Dieter Schenk (Vice Chairman)
• Roberto Fusté Dr. Walter L. Weisman
• Dr. Emanuele Gatti Rolf A. Classon
• Ron Kuerbitz William P. Johnston
• Dr. Rainer Runte Prof. Dr. Bernd Fahrholz

Share Profile – Key Data

Ticker Symbols	Ordinary shares
Frankfurt Stock Exchange	FME
New York Stock Exchange (NYSE)	FMS
Reuters: XETRA / Frankfurt Stock Exchange	FMEG.DE / FMEG.F
Bloomberg	FME GY
Security Identification Numbers
WKN	578 580
ISIN	DE 0005785802
CUSIP No. (NYSE)	358029106

Financing Instruments and Maturity Profile

	Amount in million	Coupon %	Maturity
Credit Agreement Revolver	~\$ 1,250		October 30, 2017
Credit Agreement Term Loan A	\$ 2,6001		October 30, 2017
Senior Notes 2010 - 2016	€ 250	5.50%	July 15, 2016
Senior Notes 2011 - 2016	€ 100	3-month-Euribor +3.50%	Oct. 15, 2016
Senior Notes 2007 - 2017	\$ 500	6.875%	July 15, 2017
Senior Notes 2011 - 2018	\$ 400	6.50%	September 15, 2018
Senior Notes 2011 - 2018	€ 400	6.50%	September 15, 2018
Senior Notes 2012 - 2019	\$ 800	5.625%	July 31, 2019
Senior Notes 2012 - 2019	€ 250	5.25%	July 31, 2019
Senior Notes 2011 - 2021	\$ 650	5.75%	February 15, 2021
Senior Notes 2011 - 2021	€ 300	5.25%	February 15, 2021
Senior Notes 2012 - 2022	\$ 700	5.875%	January 31, 2022
Notes (Schuldscheindarlehen) 2009 - 2014	€ 451		October 27, 2014
Accounts Receivable Facility	\$ 800		July 31, 2014

Capital Structure Contacts

¹ at the beginning before amortisation

Event	Date
Report on second quarter 2013:
Quarterly Report:	August 30, 2013
Report on third quarter 2013:
Earnings Release/Conference Call:	November 5, 2013
Quarterly Report:	November 29, 2013
Report on full year 2013
Earnings Release/Conference Call:	February 25, 2014
Analyst meeting:	February 25, 2013

Fresenius Medical Care AG & Co. KGaA Investor Relations & Corporate Communications Else-Kröner-Straße 1 61352 Bad Homburg
Oliver Maier Senior Vice President, Head of IR & CC	P:+49(0)6172-609-2525 F:+49(0)6172-609-2301
Gerrit Jost Vice President	P:+49(0)6172-609-5216
North America Terry L. Morris Vice President	P:+1-800-948-2538 F: +1-615-345-5605